bisindolylmaleimide iv has been researched along with sf 2370 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davis, PD; Hill, CH; Hurst, SA; Keech, E; Lawton, G; Nixon, JS; Turner, SE; Wilkinson, SE | 1 |
Brooks, HB; Considine, E; DeHahn, TB; Dempsey, JA; Li, T; Ogg, CA; Patel, BK; Sanchez-Martinez, C; Schultz, RM; Shih, C; Spencer, CD; Watkins, SA; Zhang, F; Zhu, G | 1 |
Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
3 other study(ies) available for bisindolylmaleimide iv and sf 2370
Article | Year |
---|---|
Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.
Topics: Animals; Binding Sites; Carbazoles; Cattle; Indoles; Maleimides; Protein Kinase Inhibitors; Rats; Structure-Activity Relationship | 1992 |
Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides.
Topics: Antineoplastic Agents; Carbazoles; Cell Division; Cell Line, Tumor; Crystallography, X-Ray; Cyclin-Dependent Kinases; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Flow Cytometry; Humans; Molecular Conformation; Pyrroles; Structure-Activity Relationship | 2003 |
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |